Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11 th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) 2009 St. Gallen Conference: Primary Therapy of Early Breast Cancer - Opinion among Germ

A German working group made up of 23 breast cancer experts discussed the results from the vote at this year's St. Gallen Consensus Conference (2009) on Primary Therapy for Early Breast Cancer and came up with some concrete recommendations for day-to-day therapeutic decisions in Germany. Due the fact that the concept of the St. Gallen Consensus Conference merely allows for a minimal consensus, the objective of the working group was to provide practice-related recommendations for day-to-day clinical decisions in Germany. One area of emphasis at St. Gallen was tumor biology as a starting point for reaching individual therapeutic decisions. Intensive discussion was necessary with respect to the clinical relevance of predictive and prognostic factors. A new addition to the area of systemic therapy was a first-ever discussion of the adjuvant administration of bisphosponates and the fact that therapy with trastuzumab in HER2 overexpression has been defined as the standard for neoadjuvant therapy. The value of taxanes as a component of (neo)adjuvant chemotherapy as well as the value of aromatase inhibitors for the endocrine adjuvant treatment of postmenopausal patients were affirmed.